|
Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232). |
|
|
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer |
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD (Inst); Pfizer (Inst) |
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer |
Research Funding - AstraZeneca (Inst); MSD (Inst) |
Travel, Accommodations, Expenses - MSD |
|
|
|
Consulting or Advisory Role - Centauri Therapeutics; Merck; Puma Biotechnology |
Speakers' Bureau - Merck; MSD |
Research Funding - Puma Biotechnology (Inst) |
Travel, Accommodations, Expenses - MSD |
|
|
Stock and Other Ownership Interests - MaxiVax |
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD; Roche |
Research Funding - MaxiVax (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck |
Travel, Accommodations, Expenses - Merck |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
|
Stock and Other Ownership Interests - Merck |
Travel, Accommodations, Expenses - Merck |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst) |
Travel, Accommodations, Expenses - Amgen |